TL;DR: Keylika is a Y Combinator Summer 2022 startup Redefining the Standard of Care for Iron Deficiency Anemia, currently active with a team of 1.
Redefining the Standard of Care for Iron Deficiency Anemia
Last verified:
Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika…
Built by LemStudio
Yes. Keylika was funded by Y Combinator in the Summer 2022 batch. Redefining the Standard of Care for Iron Deficiency Anemia
Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. Our first product is a small molecule iron drug (new molecular entity) del…
Keylika was part of Y Combinator's Summer 2022 batch.
Keylika has a team of 1 people according to Y Combinator's directory.
Keylika is currently listed as Active with a team of 1 in Y Combinator's directory.
Loading interactive view…